FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders
After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Current heads of CBER, CDER snag permanent jobs endpoints.news